Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer

Yves Denizot; Véronique Truffinet; Stéphane Bouvier; Alain Gainant; Pierre Cubertafond; Muriel Mathonnet

doi:10.1080/09629350410001664824

Elevated plasma phospholipase A2 and platelet-activating factor acetylhydrolase activity in colorectal cancer

Mediators Inflamm. 2004 Feb;13(1):53-4. doi: 10.1080/09629350410001664824.

Authors

Yves Denizot¹, Véronique Truffinet, Stéphane Bouvier, Alain Gainant, Pierre Cubertafond, Muriel Mathonnet

Affiliation

¹ Laboratoire d'immunologie, Faculté de Médecine, UMR CNRS 6101, 2 rue Dr. Marcland, Limoges, France. yves.denizot@unilim.fr

Abstract

This clinical study reports that blood levels of the pro-inflammatory mediator platelet-activating factor (PAF) did not change in colorectal cancer patients. In contrast, plasma levels of two enzymatic activities, one implicated in PAF production (i.e. phospholipase A2) and one in PAF degradation (i.e. PAF acetylhydrolase activity) were significantly elevated.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

1-Alkyl-2-acetylglycerophosphocholine Esterase / blood*
Aged
Aged, 80 and over
Colorectal Neoplasms / blood*
Colorectal Neoplasms / enzymology*
Female
Humans
Male
Middle Aged
Phospholipases A / blood*
Phospholipases A2
Prospective Studies

Substances

Phospholipases A
Phospholipases A2
1-Alkyl-2-acetylglycerophosphocholine Esterase